Type 2 Diabetes

Philis-Tsimikas shared the latest findings demonstrating inferiority after switching from daily basal insulin to weekly insulin efsitora.

Kevin Sayer joins the program to discuss the latest from Dexcom and preview where the business is headed in an evolving diabetes landscape.

A new study reveals once-weekly efsitora alfa effectively lowers blood glucose in type 2 diabetes.

Steger discussed findings from a 6-month lifestyle investigating TRE+ER and IER.

A global study reveals that universal access to semaglutide could save 28 million lives and significantly reduce obesity and diabetes worldwide.

CagriSema shows weight loss results in recent trials comparable to existing interventions.

Xue discussed her research developing a personalized prediction algorithm for predicting responders to a DPP-style intervention.

New findings reveal semaglutide significantly enhances walking ability and quality of life for patients with T2D and PAD.

The ACHIEVE-1 trial reveals orforglipron's potential as a breakthrough treatment for type 2 diabetes.

An overview of 7 presentations included as late-breaking clinical trials at ADA 2025.

In this special episode, cohosts preview the most anticipated data and explore clinical implications in diabetes and obesity.

Budoff suggests monitoring serum lipoproteins like Lp(a) and ApoB to predict cardiovascular disease risk in patients with no conventional indicators.

Lopez discusses the evolving understanding of the utility of SGLT2 inhibitors and GLP-1 RAs in heart failure care, including both HFpEF and HFrEF.

Incretin-based therapies for obesity and diabetes may be capable of treating a much wider range of diseases, including Alzheimer’s and Parkinson’s.

The pooled analysis of BROOKLYN and BROADWAY data outline obicetrapib’s impact on HbA1c reduction and a trend toward lower new-onset diabetes risk.

Khan’s presentation indicates that combination screening is the optimal method of identifying heart failure risk while minimizing the percentage of cases missed.

An ERA 2025 analysis confirms empagliflozin significantly lowers acute kidney injury risk, reassuring clinicians about its safety in at-risk patients.

Hosts break down data from the CONFIDENCE trial on the safety and efficacy of finerenone plus empagliflozin in patients with T2D and CKD.

Semaglutide’s reduction in systolic blood pressure could indicate more potential for cardiovascular protection than simply its well-known glycemic benefits.

New research has indicated that glucagon-like peptide-1 receptor agonists result in lower all-cause mortality and risk of cardiovascular events in patients with concurrent sleep apnea and type 2 diabetes.

Combination therapy with finerenone and empagliflozin significantly reduces urinary albumin levels in CKD patients.

Hosts breakdown diabetes technology updates from May 2025 and Breakthrough T1D's push for improved screening.

In this episode, hosts explore technosphere inhaled insulin (Afrezza) in comparison to standard diabetes therapies in the INHALE-3 trial.

Researchers uncover a mechanism of insulin resistance in obese adolescents, paving the way for potential interventions to prevent type 2 diabetes.

Hosts break down their biggest takeaways and detail their favorite sessions from the AACE 2025 annual meeting.